Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 MutationsDavid M. Hyman, José Baselga, Igor Puzanov et al.|New England Journal of Medicine|2015Cited by 1.7k
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische OnkologieSalah‐Eddin Al‐Batran, Elke Jäger, J. T. Hartmann et al.|Journal of Clinical Oncology|2008Cited by 784
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah‐Eddin Al‐Batran, Andrea Tannapfel, Michael Koenigsmann et al.|The Lancet Oncology|2016Cited by 738
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trialClaus Rödel, Torsten Liersch, Ullrich Graeven et al.|The Lancet Oncology|2015Cited by 723
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12Emmanouil Fokas, Michael Allgäuer, Bülent Polat et al.|Journal of Clinical Oncology|2019Cited by 536